Belpointe Asset Management LLC Trims Stake in Becton, Dickinson and Company (NYSE:BDX)

Belpointe Asset Management LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,899 shares of the medical instruments supplier’s stock after selling 90 shares during the quarter. Belpointe Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $463,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BDX. Norges Bank acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at about $761,798,000. Ontario Teachers Pension Plan Board increased its holdings in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the last quarter. Vanguard Group Inc. raised its position in Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after purchasing an additional 516,427 shares during the period. Royal Bank of Canada lifted its stake in Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after purchasing an additional 473,914 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after buying an additional 435,168 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. Finally, Barclays lifted their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $280.17.

Check Out Our Latest Report on BDX

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,597 shares of company stock valued at $2,028,786. 0.31% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $240.15 on Friday. The business has a 50-day simple moving average of $235.90 and a 200-day simple moving average of $237.94. The company has a market cap of $69.41 billion, a PE ratio of 52.90, a P/E/G ratio of 2.09 and a beta of 0.44. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.86 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 13.03 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.